Jobs
-
Sunovion has announced results from the Phase 3 GOLDEN-5 48-week safety study of SUN-101 glycopyrrolate inhalation solution in patients with moderate-to-very severe COPD. According to the company, the data show that SUN-101 was well tolerated,… Read more . . .
-
Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University have published an article in the journal Vaccine describing promising results from a study of their intranasal BD584 chlamydial antigen against… Read more . . .
-
Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity’s holdings in the company to 10%. The shares will be issued on July 26, 2016.… Read more . . .
-
Evoke Pharma has announced that a Phase 3 trial of EVK-001 intranasal metoclopramide in 205 female diabetic gastroparesis patients failed to achieve its primary endpoint, which was improvement of symptoms at Week 4. EVK-001 and… Read more . . .
-
Pulmatrix has announced topline results from the Phase 1 bioavailability trial of Pulmatrix’s PUR0200 generic tiotropium DPI initiated in January 2016 and completed in May 2016. The company had previously announced positive Phase 1b results… Read more . . .
-
Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential… Read more . . .
-
The FDA has approved St. Renatus’s Kovanaze tetracaine HCl and oxymetazoline HCl nasal spray, the company announced. The product is approved for regional anesthesia for adults and children weighing 40 kg or more who are… Read more . . .
-
Inhaler component manufacturer H&T Presspart has announced the opening of a new sales office in Montevideo, Uruguay to serve customers in the South and Central American region. In addition, Jesus Polanco, formerly Business Development Manager… Read more . . .
-
While Health Canada conducts an expedited review of a new drug submission (NDS) for naloxone nasal spray, Minister of Health Jane Philpott has signed an Interim Order temporarily allowing naloxone nasal spray imported from the… Read more . . .
-
Therapix Biosciences has entered into an agreement with the Hebrew University’s technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university’s Institute… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden